Michael Needle

Michael Needle

Company: AVEO Oncology

Job title: Chief Medical Officer


Randomized Phase II Trial of Ficlatuzumab with or Without Cetuximab in Pan-refractory, Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) 9:45 am

Acts by blocking the HGF/cMet Pathway known to mediate resistance to EGFR blockade The objective response rate for the combination of 38% in HPV negative patients Combination well toleratedRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.